Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10077096 | PMC |
| http://dx.doi.org/10.1148/rycan.220141 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
F-FLT PET and Blood-based Biomarkers for Identifying Gastrointestinal Graft versus Host Disease after Allogeneic Cell Transplantation.
Radiol Imaging Cancer
January 2025
From the Stephenson Cancer Center, University of Oklahoma Health Sciences Center, 800 NE 10th St, Oklahoma City, OK 73104 (J.H.C., L.M., S.K.V., Z.H., M.P., J.G., Y.W.); Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY (J.L., J.F.); Department of Biostatistics and Epidemiology, Hudson College of Public Health, The University of Oklahoma, Oklahoma City, Okla (S.K.V., T.G.); Experimental Transplantation and Immunotherapy Branch, National Cancer Institute, National Institutes of Health, Bethesda, Md (C.G.K., R.G.); Department of Biomedical Engineering, University of Central Oklahoma, Edmond, Okla (Z.H.); and Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta, Emory University, Atlanta, GA (K.M.W.).
Purpose To determine whether fluorine 18 (F) fluorothymidine (FLT) PET imaging alone or combined with Mount Sinai Acute GVHD International Consortium (MAGIC) biomarkers could help identify subclinical gastrointestinal graft versus host disease (GI-GVHD) by day 100 following hematopoietic stem cell transplantation (HSCT). Materials and Methods F-FLT PET imaging was analyzed in a prospective pilot study (ClinicalTrials.gov identifier no.
View Article and Find Full Text PDFEmerging Radiopharmaceuticals in Pet Imaging for Mesothelioma: A Review of [F]FDG Alternatives.
Mol Diagn Ther
November 2024
Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy.
Mesothelioma is a malignant tumor associated primarily with asbestos exposure, characterized by an aggressive nature and poor prognosis. Accurate diagnosis, staging, and monitoring of therapeutic response are crucial for effective patient management. Along with a computed tomography (CT) scan, fluorodeoxyglucose labeled with fluorine-18 ([F]FDG) positron emission tomography (PET) is commonly used in mesothelioma evaluation.
View Article and Find Full Text PDFDose-Response Relationships Between Radiation Exposure, Bone Marrow Function as Measured by F-Fluorothymidine Positron Emission Tomography, and Lymphocyte Counts During Chemoradiation for Non-Small Cell Lung Cancer.
Int J Radiat Oncol Biol Phys
September 2024
Department of Radiation Oncology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
Purpose: F-fluorothymidine (FLT) positron emission tomography (PET) enables sensitive imaging of bone marrow (BM) proliferation. Sequential FLT-PET/computed tomography scans before and during chemoradiation therapy (CRT) for non-small cell lung cancer were repurposed to investigate the dose-response effects of radiation on BM proliferation.
Methods And Materials: Twenty-six non-small cell lung cancer patients underwent platinum-based CRT to 60 Gy in 30 fractions with FLT-PET/computed tomography scans at baseline, week 2 (20 Gy), and week 4 (40 Gy).
Feasibility of identifying proliferative active bone marrow with fat fraction MRI and multi-energy CT.
Phys Med Biol
June 2024
Department of Human Oncology, University of Wisconsin-Madison, 600 Highland Ave, Madison, WI 53792, United States of America.
Active bone marrow (ABM) can serve as both an organ at risk and a target in external beam radiotherapy.F-fluorothymidine (FLT) PET is the current gold standard for identifying proliferative ABM but it is not approved for human use, and PET scanners are not always available to radiotherapy clinics. Identifying ABM through other, more accessible imaging modalities will allow more patients to receive treatment specific to their ABM distribution.
View Article and Find Full Text PDFEmerging Role of [F]FLT PET/CT in Lymphoid Malignancies: A Review of Clinical Results.
Hematol Rep
January 2024
Department of Radiological Sciences, Oncology and Anatomo-Pathology, Sapienza, University of Rome, 00161 Rome, Italy.
Fluorine-18 fluorodeoxyglucose ([F]FDG) is nowadays the leading positron emission tomography (PET) tracer for routine clinical work-ups in hematological malignancies; however, it is limited by false positive findings. Notably, false positives can occur in inflammatory and infective cases or in necrotic tumors that are infiltrated by macrophages and other inflammatory cells. In this context, 3'-deoxy-3'-[F]fluorothymidine ([F]FLT) has been shown to be a promising imaging biomarker of hematological malignant cell proliferation.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!